Molecular Fingerprinting in Exprimate Urine of the Prostate

Completed

• Conditions: Malignant neoplasm of prostate; Hyperplasia of prostate; N40; C61

• Registration Number: DRKS00025002
• Lead Sponsor: udwig-Maxilians-Universität München, Fakulät für Physik

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-04-21
• Study Completion: 2021-06-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: Male
• Target Recruitment: 220

Inclusion Criteria

Consent was given, participant is older than 18 years, belonging to one of the cohorts examined

Exclusion Criteria

The presence of several cancers, cancer treatment within the last two years before inclusion in the study, submission of spontaneous/ exprimate urine samples not possible, non-compliance of the participant

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mean and standard deviation of the global molecular fingerprint (GMF).

Secondary Outcome Measures

Name	Time	Method
1. Field-resolved spectroscopy of exprimate urine will be technically feasible.<br>2. There will be variation in GMFs among different healthy individuals (inter-personal variation) and within one individual over time (intra-personal variation). Inter-personal variation will be greater than intra-personal variation and mean differences will be > 0.8 STD (standard deviation).<br>3. GMFs will be reproducible, i.e. the GMF variation of repeated measurements of the same sample will be smaller than the inter- and intra-personal variation and the mean difference will be > 0.8 STD (standard deviation).<br>4. There will be differences in GMFs between groups of patients with prostate cancer, benign prostate hyperplasia, participants undergoing cancer screening, patients after radical prostectomy and healthy volunteers.